A Case of Graves’ Disease Following Vaccination with the Oxford-AstraZeneca SARS-CoV-2 Vaccine: Case Report and Review of the Literature

Dalia Cuenca1, Mercedes Aguilar-Soto2, Moisés Mercado3

1 Department of Endocrinology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2 Department of Internal Medicine, American British Cowdray Medical Center, Mexico City, Mexico
3 Endocrine Research Unit, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico

ABSTRACT
A 57-year-old man presented to the outpatient clinic with tremor, palpitations, weight loss and fatigue 1 week after receiving the first dose of the Oxford-AstraZeneca SARS-CoV-2 vaccine (ChAdOx1 nCoV-19). Laboratory studies showed a suppressed TSH with elevated total and free T4. Thyroid peroxidase and thyroglobulin antibodies were elevated but thyrotropin receptor autoantibodies were indeterminate. Thyroid scintigraphy with technetium Tc-99m pertechnetate revealed increased diffuse, symmetric uptake. The patient was treated with thiamazole 15 mg three times a day and propranolol with resolution of his symptoms and normalization of his thyroid function tests until discontinuation of the antithyroid drug 6 months after symptom onset.

KEYWORDS
Graves’ disease, AstraZeneca, COVID-19

LEARNING POINTS
• Thyroid autoimmunity triggered by SARS-CoV-2 vaccines is being increasingly recognized among patients with and without a history of autoimmune thyroid disease.
• Symptoms and signs of thyrotoxicosis, including fever and tachycardia, can be wrongly attributed to the systemic adverse events of these vaccines.
• Early recognition of this condition is mandatory to allow proper treatment with anti-thyroid medications and radioactive iodine when necessary.

INTRODUCTION
It has been almost 2 years since the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a global pandemic, with over 490 million cases and 6.1 million deaths reported worldwide. Seven vaccines were developed, tested and approved in an unprecedented record time and in January 2021 immunization programs began at different rates in different countries. SARS-CoV-2 vaccines include the mRNA-based Pfizer-BioNTech Comirnaty and Moderna’s Spikevax; non-replicating viral vector (adenovirus) vaccines such as Oxford-AstraZeneca, Sputnik, Janssen and CanSino Convidecia; and the inactivated virus vaccine CoronaVac (Sinovac).[1]
Overall, these vaccines have significantly reduced the number of reported cases and mortality, but have also caused variable short- and long-term adverse events, including triggering underlying autoimmune conditions such as autoimmune thyroid disease. To date, 20 cases of Graves’ disease (GD) occurring after SARS-Cov-2 vaccination have been reported, most of them following the administration of the Pfizer BioNTech mRNA vaccine. We herein report, to our knowledge, the third case of GD occurring after administration of the Oxford-AstraZeneca vaccine, which was successfully treated with thiamazole.

**CASE DESCRIPTION**

A previously healthy 57-year-old man presented to the outpatient clinic with a 5-day history of tremor, palpitations and a 3 kg weight loss as well as fatigue 1 week after receiving the Oxford-AstraZeneca SARS-CoV-2 vaccine. On physical examination, his blood pressure was 120/80 mmHg, his pulse was regular at 86 per minute, respiratory rate was 20 breaths per minute and his body temperature was 36°C. He appeared anxious but not in acute distress. Neck examination was remarkable for a palpable but painless, diffuse, symmetric, rubbery goitre approximately twice the size of a normal gland, with neither thrill nor murmurs, and no lymphadenopathies. Cardiopulmonary examination was normal, without murmurs or friction rubs. The abdomen was supple, with no hepatosplenomegaly and a somewhat increased peristalsis. Neurological examination was remarkable for a fine distal tremor and hyperreflexia.

Laboratory work-up showed a suppressed TSH with elevated free and total thyroid hormones with positive anti-thyroglobulin (Tg) and anti-thyroid peroxidase (TPO) autoantibodies, and indeterminate thyrotropin receptor autoantibodies (TRAb) (Table 1). Blood chemistry and a complete blood count were within normal limits. Thyroid ultrasound showed a diffusely enlarged gland with increased vascularity. Thyroid scintigraphy with technetium Tc-99m pertechnetate revealed a diffuse goitre with increased uptake (Fig. 1).

![Thyroid scintigraphy with technetium Tc-99m pertechnetate showing diffuse increased uptake](image)

|                      | At presentation | 12 Weeks on thiamazole | 12 Weeks off thiamazole |
|----------------------|-----------------|------------------------|------------------------|
| **TSH**              | <0.005 mIU/l    | 26.3 mIU/l             | 1.2 mIU/l              |
| (normal 0.3–3 mIU/l) |                 |                        |                        |
| **Free T4**          | 4 ng/dl         | 0.5 ng/dl              | 0.98 ng/dl             |
| (normal 0.6–1.2 ng/dl) |              |                        |                        |

The patient was treated with thiamazole 15 mg three times a day and propranolol 20 mg twice a day. Symptoms of hyperthyroidism gradually resolved and after 3 months of treatment, his thyroid function tests showed frank hypothyroidism, and so the thiamazole was stopped. At his last follow-up visit, 3 months after discontinuation of thiamazole (6 months after initial presentation), he was found clinically and biochemically euthyroid.
DISCUSSION

Since immunization against COVID-19 began in January 2021, 20 cases of GD occurring after vaccination have been reported (Table 2). Eighteen of these 20 patients (90%) had received an mRNA vaccine (Pfizer in 16 and Moderna in 2) and only two had been immunized with the Oxford-AstraZeneca non-replicating adenoviral vector vaccine (Table 2). Fourteen of these patients had no history of thyroid autoimmune disease (new onset, 70%), while 6 had been diagnosed with GD several years before vaccination and were all considered to be in remission (reactivation, 30%). Thus, our patient is the second reported case of new-onset GD occurring as a result of a non-replicating adenoviral vector vaccine.

SARS-CoV-2 infection is known to activate both the innate and adaptive immune response. Patients with a severe form of the disease usually develop an acute inflammatory state characterized by the synthesis and secretion of several proinflammatory cytokines that ultimately cause multiorgan failure. This so-called ‘cytokine storm’ is an exaggerated cellular immune response that more frequently than expected results in autoimmune conditions including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and haemophagocytic lymphohistiocytosis[2].

Several autoimmune adverse events have been reported in patients receiving both mRNA and adenoviral vector COVID-19 vaccinations, including immune thrombocytopenic purpura, autoimmune hepatitis, Guillain-Barre syndrome, IgA nephropathy, aplastic anaemia, autoimmune bullous disease, rheumatoid arthritis and systemic lupus erythematosus[3]. Our patient presented with the classic symptoms and signs of hyperthyroidism less than 1 week after receiving the Oxford-AstraZeneca COVID-19 vaccine, with clinical and laboratory features consistent with GD. Although SARS-CoV-2-induced subacute thyroiditis has also been reported[4], we are certain that our patient had GD, mainly because of his diffusely hypercaptating thyroid scan.

GD has been reported in 14 patients with no prior history of autoimmune thyroid disease[3,5–11], while the remaining 6 had previously been diagnosed with hyperthyroidism but were in remission and were thus considered to have reactivations[6,12–16]. The mean age of these patients was 47.3 ± 14.8 years (range 28–71), 15 were women and 5 were men. The median time from vaccination to the onset of symptoms was 16 days (range 2–60). Anti-thyroid peroxidase (TPO) and anti-thyroglobulin (Tg) autoantibodies were present in 11 (55%) and 8 (40%) patients, respectively, while positive thyroid stimulating immunoglobulin (TSI) or TSH-receptor antibodies were present in 100%. No significant clinical or biochemical differences between the new onset and the reactivation cases were identified.

Including the present case, there are three reports of GD occurring after immunization with the Oxford-AstraZeneca vaccine, which accounts for only 14.2% of the cases of SARS-CoV-2 vaccination-induced autoimmune thyroid disease. Although the sample size is not large enough to allow a formal statistical analysis, all three patients receiving this adenoviral vector vaccine developed symptoms of GD less than 1 week after immunization, in contrast to the 18 mRNA vaccine-induced cases, where time to onset was as long as 60 days, with a median of 18 days.

Of the two previously reported cases of AstraZeneca vaccine-induced GD[11,16], one occurred in a female patient who had a prior history of autoimmune hyperthyroidism but was in remission and the other one in a male patient with no history of thyroid diseases. Both patients still required thiamazole to maintain euthyroidism 30–60 days after the onset of GD. In contrast, our patient responded rapidly and completely to thiamazole to the point of becoming frankly hypothyroid after 3 months of treatment. A few weeks after discontinuation of thiamazole, his thyroid function tests returned to normal and have remained so up to his last visit 8 months after the diagnosis of GD.

Regarding the pathophysiology of these adverse reactions, mechanisms such as molecular mimicry, the production of particular autoantibodies and an adjuvant-mediated effect have been proposed. In an in vitro study, Vojdani et al. found that antibodies against the SARS-CoV-2 spike protein cross-react with TPO. Furthermore, there is a non-negligible sequence homology between TPO and several SARS-CoV-2 proteins, including the spike protein[17]. Adjuvants are well known to trigger autoimmune diseases such as GD in genetically susceptible individuals[17]. Although the novel mRNA vaccines do not include a traditional adjuvant, the liposome that transports the genetic material can bind toll-like receptors (TLR) and can trigger an aberrant immune response[18].
| Country    | Vaccine                  | New | Reactivation | Age/sex | Time to GD (days) | Free T4 (ng/dl) | Antibodies                  | Reference |
|------------|--------------------------|-----|--------------|---------|------------------|----------------|-----------------------------|-----------|
| Mexico     | mRNA (Pfizer)            | 2   |              | 40 F    | 2                | 4.57           | TPO, Tg, TSI, TSH-R         | [5]       |
|            |                          |     |              | 28 F    | 3                | 1.84           | TPO, Tg, TSH-R              |           |
| Austria    | mRNA (Pfizer)            | 1   | 1            | 46 M*   | 15               | 1.63           | TSH-R                      | [6]       |
|            |                          |     |              | 71 F*   | 15               | 3.56           | TSH-R                      |           |
| China      | mRNA (Pfizer)            | 1   |              | 40 F    | 35               | 5.17           | TPO, Tg, TSH-R              | [12]      |
| USA        | mRNA (Pfizer)            | 1   |              | 50 F    | 3                | Normal*        | TSI                        | [13]      |
| USA        | mRNA (Pfizer)            | 1   |              | 71 F    | 15               | 7.2*           | TPO, TSI                   | [14]      |
| USA        | mRNA (Pfizer)            | 1   |              | 32 M    | 10               | 5.41           | TPO, Tg, TSI               | [7]       |
| Spain      | mRNA (3 Pfizer, 1 Moderna)| 4   |              | 71 F    | 60               | 2.3            | TPO, TSH-R, TSH-R          | [8]       |
|            |                          |     |              | 42 F    | 14               | 2.9            | TSH-R                      |           |
|            |                          |     |              | 54 F    | 14               | 4.7            | TPO, Tg, TSH-R             |           |
|            |                          |     |              | 46 F    | 50               | 3.2            | TPO, Tg, TSH-R             |           |
| USA        | mRNA (2, Pfizer, 1 Moderna)| 2   | 1            | 38 F    | 5                | 8.3            | TPO, TSI, TSH-R            | [9]       |
|            |                          |     |              | 30 M    | 30               | 1.8            | TSI                        |           |
|            |                          |     |              | 63 F    | 4                | 2.4            | TPO, TSI, TSH-R            |           |
| Spain      | mRNA (Pfizer)            | 1   |              | 38 F    | 12               | 2.01           | Tg, TSI                    | [3]       |
| Belgium    | mRNA (Pfizer)            | 1   |              | 34 F    | 10               | 2.54           | TSH-R                      | [15]      |
| Italy      | mRNA (Pfizer)            | 1   |              | 52 M    | 28               | 5.56           | TPO, Tg, TSH-R             | [10]      |
| Thailand   | Adenovirus (Oxford-AZ)   | 1   |              | 30 F    | 4                | 1.29           | TSH-R                      | [16]      |
| Thailand   | Adenovirus (Oxford-AZ)   | 1   |              | 70 M    | 2                | 3.19           | TSH-R                      | [11]      |
| Mexico     | Adenovirus (Oxford-AZ)   | 1   |              | 57 M    | 5                | 4              | TPO, Tg, TRAb (?)          | Our case |

Table 2. Summary of Graves' disease cases occurring after immunization with SARS-CoV-2 vaccine

a New disease. b Reactivation. c Radioactive iodine 10 years prior, on L-T4 replacement. Graves ophthalmopathy. d Thyroid storm.
REFERENCES

1. WHO. Weekly epidemiological update on COVID-19 - April 7th 2022. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed April 7 2022)

2. Liu Y, Savalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol 2021;33(2):155–162. doi:10.1097/BOR.0000000000001776

3. Pujol A, Gómez LA, Gallegos C, Nicolau J, Sanchis P, González-Freire M, et al. Thyroid as a target of adjuvant autoimmunity/inflammatory syndrome due to mRNA-based SARS-CoV2 vaccination: from Graves’ disease to silent thyroiditis. J Endocrinol Invest 2022 Apr;45(4):875–882. doi:10.1007/s40618-021-01707-0

4. Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology 2022 Apr;165(4):386–401. doi:10.1111/imn.13443

5. Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, Medina G, Sánchez Valadez TI, Jara LJ. Two cases of Graves’ disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid 2021;31(9):1436–1439. doi:10.1089/thy.2021.0142

6. Zettinig G, Krebs M. Two further cases of Graves’ disease following SARS-CoV-2 vaccination. J Endocrinol Invest 2022;45(1):227–228. doi:10.1007/s40618-021-01650-0

7. Hanouche W, El Soufi Y, Abzaq S, Okafor BV, Zhang F, Paras C. A case report of new-onset Graves’ disease induced by SARS-CoV-2 infection or vaccine?: J Clin Transl Endocrinol Case Rep 2022;2:100104. doi:10.1016/j.jctr.2021.100104

8. Pla Peris B, Merchant Alfaro AA, Maravall Royo FJ, Abellán Galiana P, Pérez Naranjo S, González Boillos M. Thyrotoxicosis following SARS-CoV-2 vaccination: a case series and discussion. J Endocrinol Invest 2022Jan 11;1:1–7. doi:10.1007/s40618-022-01739-0. Online ahead of print.

9. Weintraub MA, Ameer B, Sinha Gregory N. Graves disease following the SARS-CoV-2 vaccine: case series. J Investig Med High Impact Case Rep 2021;9:23247096211106356. doi:10.1177/23247096211106356

10. Patrizio A, Ferrari SM, Antonelli A, Fallahi P. A case of Graves’ disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J Autoimmun 2021;125:102738. doi:10.1016/j.jaut.2021.102738

11. Sriphrapradang C, Shantavasinkul PC. Graves’ disease following SARS-CoV-2 vaccination. Endocrine 2021;74(3):473–474. doi:10.1007/s12020-021-02902-y

12. Lui DTW, Lee KK, Lee CH, Lee ACH, Hung IFN, Tan KCB. Development of Graves’ disease after SARS-CoV-2 mRNA vaccination: a case report and literature review. Front Public Health 2021;9:778964. doi:10.3389/fpubh.2021.778964

13. Rubinstein TJ. Thyroid eye disease following COVID-19 vaccine in a patient with a history Graves’ disease: a case report. Ophthalmic Plast Reconstr Surg 2021;37(6):e221–e223. doi:10.1097/IOP.0000000000002059

14. Goblirsch TJ, Paulson AE, Tasko G, Mekonnen AJ. Graves’ disease following administration of second dose of SARS-CoV-2 vaccine. BMJ Case Rep 2021;14(12):e246432. doi:10.1136/bcr-2021-246432

15. Rubinstein TJ. Thyroid eye disease following COVID-19 vaccine in a patient with a history Graves’ disease: a case report. Ophthalmic Plast Reconstr Surg 2021;37(6):e221–e223. doi:10.1097/IOP.0000000000002059

16. Sriphrapradang C. Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves’ disease. Endocrine 2021;74(2):226–227. doi:10.1007/s12020-022-02879-8

17. Vojdani A, Vojdani E, Kharrazi D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol 2021;Jan 19;11:617089. doi:10.3389/fimmu.2020.617089

18. Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol 2021;21(4):195–197. doi:10.1038/s41577-021-005

DOI: 10.12890/2022_003275